Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
INTERVIEW Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
REGULATORY Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
-
REGULATORY CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
-
REGULATORY New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
-
ACADEMIA AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
-
REGULATORY MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
-
TRENDS Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
REGULATORY With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
-
BUSINESS Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
-
BUSINESS Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
-
REGULATORY MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
-
REGULATORY Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
-
BUSINESS Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
-
BUSINESS Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
-
REGULATORY Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
-
REGULATORY Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
-
REGULATORY Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
-
INTERVIEW CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
February 8, 2017
-
TRENDS Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
BUSINESS Takeda Wants to Be Global GI Leader in 2025, Not in Acquisition Frenzy Mode: CEO
February 3, 2017
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…